tyrphostin AGL-2043

a potent tricyclic quinoxaline inhibitor of PDGF beta-receptor tyrosine kinase (PTK), Kit, and Flt3

Also Known As:

AGL-2043

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzylidene Compounds: 10
        Tyrphostins: 183
        tyrphostin AGL-2043: 3
- Nitriles: 227
  - Tyrphostins: 183
    - tyrphostin AGL-2043: 3
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinoxalines: 324
      - Tyrphostins: 183
        tyrphostin AGL-2043: 3

Experts

1.	Banai, Shmuel: 2 articles (02/2005 - 10/2004)
2.	Chorny, Michael: 2 articles (02/2005 - 10/2004)
3.	Gertz, S David: 2 articles (02/2005 - 10/2004)
4.	Golomb, Gershon: 2 articles (02/2005 - 10/2004)
5.	Lazarovichi, Galila: 2 articles (02/2005 - 10/2004)
6.	Levitzki, Alexander: 2 articles (02/2005 - 10/2004)
7.	Andronescu, Ecaterina: 1 article (04/2020)
8.	Beshchasna, Natalia: 1 article (04/2020)
9.	Duta, Oana Cristina: 1 article (04/2020)
10.	Ficai, Anton: 1 article (04/2020)

Related Diseases

1.	Neointima 10/01/2004 - "The present study was designed to determine the effect of AGL-2043 delivered from a stent-based, biodegradable polymeric coating on neointima formation in the porcine coronary artery model. " 02/01/2005 - "In the pig model, intramural delivery of AGL-2043 resulted in reduced in-stent neointima formation in the coronary arteries over control despite similar degrees of wall injury. " 10/01/2004 - "Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries."
2.	Hyperplasia 10/01/2004 - "Stent-based delivery of tyrphostin AGL-2043 from a biodegradable polymeric coating reduces in-stent neointimal hyperplasia in porcine coronary arteries by 50% after 28 days and preserves lumen area. " 04/13/2020 - "DES were developed to reduce the tissue hyperplasia and in-stent restenosis utilizing antiproliferative substances like paclitaxel, limus (siro-, zotaro-, evero-, bio-, amphi-, tacro-limus), ABT-578, tyrphostin AGL-2043, genes, etc. The innovative solutions aim at overcoming the main limitations of the stent technology, such as in-stent restenosis and stent thrombosis, while maintaining the prime requirements on biocompatibility, biodegradability, and mechanical behavior. "
3.	Thrombosis (Thrombus) 04/13/2020 - "DES were developed to reduce the tissue hyperplasia and in-stent restenosis utilizing antiproliferative substances like paclitaxel, limus (siro-, zotaro-, evero-, bio-, amphi-, tacro-limus), ABT-578, tyrphostin AGL-2043, genes, etc. The innovative solutions aim at overcoming the main limitations of the stent technology, such as in-stent restenosis and stent thrombosis, while maintaining the prime requirements on biocompatibility, biodegradability, and mechanical behavior. "
4.	Inflammation (Inflammations) 10/01/2004 - "There were no significant differences between control and AGL-2043 in injury score (1.24+/-0.11 vs. 1.15+/-0.12, p=0.07) or inflammation score (1.19+/-0.35 vs. 1.07+/-0.33, p=0.41). "
5.	Pathologic Constriction (Stenosis) 10/01/2004 - "After 28 days, histomorphometric analysis showed that in-stent stenosis in animals treated with AGL-2043 was reduced by 50% (51+/-21% versus 26+/-10%, p=0.001), the absolute neointimal area was reduced by 44% (2.38+/-1.04 versus 1.31+/-0.43 mm(2), p=0.004), and the absolute luminal area was increased by 57% (2.19+/-1.09 versus 3.39+/-0.59 mm(2), p=0.003). "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Phenobarbital (Luminal)
3.	zotarolimus

Related Therapies and Procedures

1.	Stents